Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma
Maurício Fernando Silva Almeida Ribeiro1, Luiza Lara Gadotti1, Karina Perez Sacardo1
1Oncology Center, Hospital Sírio-Libanês, São Paulo, Brazil.
Abstract:
Chromosomal rearrangements involving the c-ros oncogene 1 (ROS1) gene define a subset of non-small cell lung cancers highly sensitive to small-molecule tyrosine kinase inhibitors. However, little is known about the impact of different fusion partners on tyrosine kinase inhibitor efficacy. We herein describe a case of a 26-year-old never-smoker patient from southern Africa with metastatic lung adenocarcinoma driven by SLC12A2-ROS1 fusion, who had a pronounced and durable response to crizotinib. The present case underscores the importance of pursuing actionable alterations in patients with similar clinical and epidemiological characteristics. In addition, provides the second report of crizotinib activity against lung malignancies harboring the unique SLC12A2-ROS1 fusion and highlights the importance of a deeper understanding of molecular alterations in underrepresented subgroups of patients to tailor the decision-making in daily practice.
Insights
A rare SLC12A2-ROS1 gene fusion drove lung cancer in a young, never-smoking patient. Crizotinib provided a significant and lasting response, highlighting the need for molecular testing in diverse patient groups.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Chromosomal rearrangements of the ROS1 gene are key drivers in a subset of non-small cell lung cancers (NSCLC).
- These ROS1-rearranged NSCLCs are typically sensitive to small-molecule tyrosine kinase inhibitors (TKIs).
- The influence of specific fusion partners on TKI efficacy remains incompletely understood.
Observation:
- A 26-year-old, never-smoking patient from Southern Africa presented with metastatic lung adenocarcinoma.
- Genetic analysis revealed a unique SLC12A2-ROS1 gene fusion as the underlying driver.
- The patient experienced a remarkable and sustained response to crizotinib treatment.
Findings:
- This case represents the second report demonstrating crizotinib's effectiveness against lung malignancies with the SLC12A2-ROS1 fusion.
- The specific fusion partner (SLC12A2) did not impede TKI sensitivity.
Implications:
- Identifying actionable molecular alterations, such as ROS1 fusions, is crucial for effective NSCLC treatment, particularly in underrepresented populations.
- This case emphasizes the importance of comprehensive molecular profiling to guide personalized therapy decisions in daily clinical practice.
- Further research into diverse fusion partners and their impact on TKI response is warranted to optimize treatment strategies for all NSCLC patients.
More Related Videos
09:49Oncogenic Gene Fusion Detection Using Anchored Multiplex Polymerase Chain Reaction Followed by Next Generation Sequencing
Published on: July 5, 2019
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:23Abnormal Proliferation